Targeting HER 1 and 2 in breast cancer with lapatinib

Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, deve...

Full description

Bibliographic Details
Main Author: Gerald M. Higa
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://oncologyreviews.org/index.php/or/article/view/105